Intech Investment Management LLC grew its stake in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 123.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 192,699 shares of the medical research company’s stock after buying an additional 106,642 shares during the period. Intech Investment Management LLC’s holdings in Edwards Lifesciences were worth $16,634,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Legacy Trust raised its position in shares of Edwards Lifesciences by 1.4% during the third quarter. Legacy Trust now owns 7,409 shares of the medical research company’s stock valued at $682,000 after buying an additional 104 shares during the last quarter. Bessemer Group Inc. grew its position in Edwards Lifesciences by 0.4% during the third quarter. Bessemer Group Inc. now owns 28,358 shares of the medical research company’s stock worth $2,447,000 after buying an additional 114 shares in the last quarter. Flagship Harbor Advisors LLC grew its position in Edwards Lifesciences by 1.2% during the third quarter. Flagship Harbor Advisors LLC now owns 10,615 shares of the medical research company’s stock worth $916,000 after buying an additional 125 shares in the last quarter. Fifth Third Wealth Advisors LLC grew its position in Edwards Lifesciences by 1.8% during the third quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company’s stock worth $627,000 after buying an additional 132 shares in the last quarter. Finally, Calamos Wealth Management LLC increased its stake in Edwards Lifesciences by 6.1% during the third quarter. Calamos Wealth Management LLC now owns 2,438 shares of the medical research company’s stock valued at $210,000 after acquiring an additional 141 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $104.25, for a total value of $64,530.75. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $4,173,544.50. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald Bobo, Jr sold 48,900 shares of Edwards Lifesciences stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $103.05, for a total value of $5,039,145.00. Following the completion of the transaction, the vice president directly owned 22,798 shares of the company’s stock, valued at $2,349,333.90. This represents a 68.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 53,945 shares of company stock valued at $5,498,306. 0.31% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on Edwards Lifesciences
Edwards Lifesciences Price Performance
Shares of Edwards Lifesciences stock opened at $107.16 on Monday. The firm’s 50-day moving average price is $90.42 and its two-hundred day moving average price is $86.32. Edwards Lifesciences Corporation has a 1-year low of $74.66 and a 1-year high of $107.69. The stock has a market capitalization of $61.62 billion, a price-to-earnings ratio of 60.54, a P/E/G ratio of 2.86 and a beta of 0.85. The company has a current ratio of 4.60, a quick ratio of 3.86 and a debt-to-equity ratio of 0.05.
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.06. The firm had revenue of $1.72 billion during the quarter, compared to the consensus estimate of $1.68 billion. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.67 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 3.01 earnings per share for the current fiscal year.
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
See Also
- Five stocks we like better than Edwards Lifesciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
